CL2021000592A1 - Método para producir un arenavirus antitumoral así como mutantes de arenavirus - Google Patents

Método para producir un arenavirus antitumoral así como mutantes de arenavirus

Info

Publication number
CL2021000592A1
CL2021000592A1 CL2021000592A CL2021000592A CL2021000592A1 CL 2021000592 A1 CL2021000592 A1 CL 2021000592A1 CL 2021000592 A CL2021000592 A CL 2021000592A CL 2021000592 A CL2021000592 A CL 2021000592A CL 2021000592 A1 CL2021000592 A1 CL 2021000592A1
Authority
CL
Chile
Prior art keywords
arenavirus
antitumor
mutants
produce
well
Prior art date
Application number
CL2021000592A
Other languages
English (en)
Spanish (es)
Inventor
Karl Lang
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Original Assignee
Abalos Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics Gmbh filed Critical Abalos Therapeutics Gmbh
Publication of CL2021000592A1 publication Critical patent/CL2021000592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2021000592A 2018-09-12 2021-03-10 Método para producir un arenavirus antitumoral así como mutantes de arenavirus CL2021000592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Publications (1)

Publication Number Publication Date
CL2021000592A1 true CL2021000592A1 (es) 2021-09-10

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000592A CL2021000592A1 (es) 2018-09-12 2021-03-10 Método para producir un arenavirus antitumoral así como mutantes de arenavirus

Country Status (18)

Country Link
US (2) US12129281B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019533A1 (cg-RX-API-DMAC7.html)
JP (1) JP7583448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210057782A (cg-RX-API-DMAC7.html)
CN (2) CN120158432A (cg-RX-API-DMAC7.html)
AU (1) AU2019340845B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004451A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111305A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000592A1 (cg-RX-API-DMAC7.html)
DE (1) DE102018215551A1 (cg-RX-API-DMAC7.html)
DK (1) DK3694868T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908854T3 (cg-RX-API-DMAC7.html)
IL (1) IL281299B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002937A (cg-RX-API-DMAC7.html)
PH (1) PH12021550424A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101970UA (cg-RX-API-DMAC7.html)
WO (1) WO2020053324A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101833B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes
IL326615A (en) * 2023-08-31 2026-04-01 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells
CN117867030A (zh) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用
CN122357626A (zh) * 2025-10-30 2026-07-10 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
CN102439146A (zh) 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
JP6162818B2 (ja) * 2012-12-12 2017-07-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN110167586B (zh) * 2016-11-04 2024-01-30 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Also Published As

Publication number Publication date
MX2021002937A (es) 2021-07-16
ZA202101833B (en) 2022-10-26
SG11202101970UA (en) 2021-03-30
WO2020053324A1 (en) 2020-03-19
EP3694868A1 (en) 2020-08-19
ES2908854T3 (es) 2022-05-04
US12129281B2 (en) 2024-10-29
DE102018215551A1 (de) 2020-03-12
JP7583448B2 (ja) 2024-11-14
EP3694868B1 (en) 2021-11-03
NZ774584A (en) 2024-09-27
IL281299B2 (en) 2025-07-01
CN112996802A (zh) 2021-06-18
CN120158432A (zh) 2025-06-17
IL281299B1 (en) 2025-03-01
US20250122244A1 (en) 2025-04-17
EP4019533A1 (en) 2022-06-29
CN112996802B (zh) 2025-03-11
KR20210057782A (ko) 2021-05-21
US20220033445A1 (en) 2022-02-03
JP2022500054A (ja) 2022-01-04
IL281299A (en) 2021-04-29
AU2019340845B2 (en) 2026-01-29
CA3111305A1 (en) 2020-03-19
BR112021004451A2 (pt) 2021-06-01
PH12021550424A1 (en) 2021-09-20
DK3694868T3 (da) 2022-02-07
AU2019340845A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2021002937A (es) Metodo para producir un arenavirus antitumoral asi como mutantes de arenavirus.
MX2025003310A (es) Integracion dirigida de acidos nucleicos
PH12019502333A1 (en) Targeted compositions
PH12021500014A1 (en) Fused ring compounds
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
EP4483881A3 (en) Fused ring compounds
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
EA202090817A1 (ru) Триспецифические белки и способы их применения
MX2019000216A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
BR112017005987A2 (pt) ponta ultrassônica para instrumento ultrassônico e método de tratamento dentário com a referida ponta ultrassônica.
BR112016023707A2 (pt) método para produzir l-aminoácidos com o uso de uma bactéria alcalifílica
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
AU2016316202A8 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2018132821A3 (en) Elastomeric proteins
CL2019002848A1 (es) Método de producción de proteínas de doble función y sus derivados.
CY1118704T1 (el) Ανθρωπινος πληθυσμος βλαστοκυτταρων του τραχηλου της μητρας και χρησεις αυτου
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
BR112018013967A2 (pt) vacinas contra o câncer
WO2019147979A3 (en) Peptides for angiogenic therapy